retatrutide approval status 2025 HAS NOT BEEN APPROVED YET & CURRENTLY IN PHASE III CLINICAL TRIALS⛔️ Retatrutide is not currently FDA-approved, as it is in Phase III clinical trials with anticipated completion in 2025–2026 and Can You Access Retatrutide Before
Description
Medicare Part D coverage expansion: The proposed CMS rule allowing Medicare Part D plans to cover anti-obesity medications would make 31 million Medicare beneficiaries with obesity eligible for semaglutide and tirzepatide, representing a USD 55.8 billion annual drug spend potential at 15% initial penetration

Nature 562:589594

We look for the whispers, makeup settling differently or subtle hollowingbefore it becomes a problem

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy